Profile image of Julia J Wattacheril, MD, MPH

Julia J Wattacheril, MD, MPH

Director of the Nonalcoholic Fatty Liver Disease Program
Attending, New York - Presbyterian Hospital

Call (212) 305-0914 for appointments.
1

About Julia J Wattacheril, MD, MPH:

Dr. Wattacheril's clinical specialties include all aspects of transplant hepatology, general hepatology and gastroenterology with emphasis on metabolic liver disease and obesity. She specializes in nonalcoholic fatty liver disease as well as all forms of hepatitis, chronic liver disease, and liver cancer in addition to liver transplantation. Her research interests include hepatic steatosis, insulin resistance, gut hormones and metabolic liver disease in adults. Her current research concentrates on the relationship between proteins and lipids that differentiate steatosis from steatohepatitis using an integrated omics approach.

Visit The Center for Liver Disease and Transplantation at columbiasurgery.org/liver

Expertise:

Chronic Liver Disease
Gastroenterology
Hereditary Liver Disease
Liver Disease
Liver Transplant
Liver Transplantation
Non-Alcoholic Fatty Liver Disease
Non-Alcoholic Steatohepatitis
Transplant Hepatology

Honors:

2024 Department of Surgery Innovation Award

2024 Department of Biomedical Engineering Ignite Award

2003 Alpha Omega Alpha

2000 Glasgow-Rubin Achievement Citation recipient, American Medical Women’s Association

Interests:

Nonalcoholic Fatty Liver Disease (NAFLD)
Insulin Resistance
Hepatocellular carcinoma
Metabolic liver diseases
OMICs
Lipid metabolism
Transplant hepatology
Body Composition

Languages:

Spanish

Appointments:

Associate Professor of Medicine at CUMC

Education:

Medical School: 2004 Baylor College of Medicine
Residency: Baylor College of Medicine
Fellowship: Vanderbilt University Medical Center
Fellowship: 2011 NewYork-Presbyterian Hospital/Columbia University Medical Center

New Patients:

YES

Locations

Primary Locations:

CUIMC/Presbyterian Hospital and Vanderbilt Clinic

622 West 168th Street
Floor 14
New York, NY 10032

For new and current patient appointments, call:
(212) 305-0914

Insurances:

Please contact the doctor's office directly to verify that your particular insurance is accepted.

AETNA [HMO, Aetna Signature Administrators, Student Health, NY Signature]
Amida Care [Special Needs]
CIGNA [POS, EPO, Great West (National), Medicare Managed Care, PPO]
Emblem/GHI [PPO, Medicare Managed Care]
Emblem/HIP [Vytra, Select Care (Exchange), POS]
Empire Blue Cross Blue Shield HealthPlus [Essential Plan]
Empire Blue Cross/Blue Shield [Medicare Managed Care]
Local 1199 [Local 1199, NYP Employee Plan]
Medicare [Traditional Medicare, Railroad]
Multiplan [Multiplan]
UnitedHealthcare [Empire Plan, Compass (Exchange), HMO, PPO, POS, Oxford Liberty, Oxford Freedom, Oxford HMO]
VNSNY CHOICE [SelectHealth]
World Trade Center Health Plan [World Trade Center Health Plan]

Publications:

Basile AO, Verma A, Tang LA, Serper M, Scanga A, Farrell A, Destin B, Carr RM, Anyanwu-Ofili A, Rajagopal G, Krikhely A, Bessler M, Reilly MP, Ritchie MD, Tatonetti NP, Wattacheril J. Rapid identification and phenotyping of nonalcoholic fatty liver disease patients using a machine-based approach in diverse healthcare systems. Clin Transl Sci. 2025 Jan;18(1):e70105. doi: 10.1111/cts.70105. PubMed PMID: 39739635; PubMed Central PMCID: PMC11686338.

A Single Dose of Phosphoinositide-3-kinase Inhibitor Alpelisib Induces Insulin Resistance in Healthy Adults: A Randomized Feasibility Study. Cook JR, Bedeir N, Sone ZD, Wattacheril J, Ginsberg HN, Laferrère B. Diabetes. 2024 Sep 12:db240402. doi: 10.2337/db24-0402. Online ahead of print. PMID: 39264822

A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24. PMID: 37363821 Free PMC article.

A global research priority agenda to advance public health responses to fatty liver disease. Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Hagström H, Huang TT, Wajcman DI, Kautz A, Kopka CJ, Krag A, Miller V, Newsome PN, Rinella ME, Romero D, Sarin SK, Silva M, Spearman CW, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg JM, Wong VW, Younossi ZM; Healthy Livers, Healthy Lives Collaborators. J Hepatol. 2023 Sep;79(3):618-634. doi: 10.1016/j.jhep.2023.04.035. Epub 2023 Jun 20. PMID: 37353401

Using epigenomics to understand cellular responses to environmental influences in diseases. Wattacheril JJ, Raj S, Knowles DA, Greally JM. PLoS Genet. 2023 Jan 19;19(1):e1010567. doi: 10.1371/journal.pgen.1010567. eCollection 2023 Jan. PMID: 36656803 Free PMC article. Review.

Health Disparities in Screening, Diagnosis, and Treatment of Hepatocellular Carcinoma. Guo A, Pomenti S, Wattacheril J.
Clin Liver Dis (Hoboken). 2021 Jun 4;17(5):353-358. doi: 10.1002/cld.1057. eCollection 2021 May.
PMID: 34136141 Free PMC article. Review. No abstract available.

*Pomenti S, Gandle C, Abu Sbeih H, Phipps M, Livanos A, Guo A, Yeh J, Burney H, Liu H, Dakhoul L, Kettler C, Gawrieh S, deLemos A, Scanga A, Chalasani N, Miller E, Wattacheril J. Hepatocellular Carcinoma in Hispanic Patients: Trends and Outcomes in a Large United States Cohort. Hep Communications2020: doi.org/10.1002/hep4.1575

*Phipps M, Livanos A, Guo A, Pomenti S, Yeh J, Dakhoul L, Burney H, Kettler C, Liu H, Miller E, GawriehS, deLemos A, Scanga A, Chalasani N, Wattacheril J. Gender Matters: Characteristics of Hepatocellular Carcinoma in Women from a Large, Multicenter Study in the United States. Am J Gastroenterol2020: doi: 10.14309/ajg.0000000000000643.

deLemos, A, Patel M, Gawrieh S, Burney H, Dakhoul L, Miller E, Scanga A, Kettler C, Liu H, Roche P, Wattacheril J, Chalasani N. Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients with Alcohol-Related Liver Disease: A US Multicenter Study. Clin Transl Gastroenterol2020: doi: 10.14309/ctg.0000000000000139.

Siddiqui MS, Van Natta ML, Connelly MA, Vuppalanchi R, Neuschwander-Tetri BA, Tonascia J, Guy C, Loomba R, Dasarathy S, Wattacheril J, Chalasani N, Sanyal AJ; NASH-CRN. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. J Hepatology2020 doi: 10/1016/j.hep.2019.10.006

*Gawrieh S, Dakhoul L, Miller E, Scanga A, deLemos A, Kettler C, Burney H, Liu H, Abu-Sbeih H, Chalasani N, Wattacheril J. Characteristics, Aetiologies and Trends of Hepatocellular Carcinoma in Patients without Cirrhosis: A United States Multicenter Study. Alimentary Pharmacology and Therapeutics.2019 doi.org/10.1111/apt15464

Wattacheril J, Shea PR, Mohammad S, Behlin C, Aggarwal V, Wilson LA, Yates KP, Ito J, Fishbein M, Stong N, Lavine JE, Goldstein DB. Exome sequencing of an adolescent with nonalcoholic fatty liver disease identifies a clinically actionable case of Wilson Disease. Cold Spring Harb Mol Case Stud.2018 Oct 1.doi: 0.1101/mcs.a003087

Wattacheril J, Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston JP, Loomba R, Brunt EM, Chen YI, Goodarzi MO, Taylor KD, Yates KP, Tonascia J, Rotter JI. Genome Wide Associations Related to Hepatic Histology in Nonalcoholic Fatty Liver Disease in Hispanic Boys. J Pediatr. 2017 Nov. doi:10.1016/j.jpeds.2017.08.004

Wattacheril J, Rose, K.L., Hill, S., Lanciault, C., Murray, C.R., Washington, K., Williams, B., English, W., Spann, M., Clements, R., Abumrad, N., and Flynn, C.R.(2017) NAFLD Phosphoproteomics: A Functional Piece of the Precision Puzzle. Hepatol Res, doi:10.1111/hepr.12885.

Corey KE, Gawrieh S, deLemosAS, Zheng H, Scanga AE, Haglund JW, Sanchez J, Danford CJ, Comerford M, BossiK, Munir S, Chalasani N, Wattacheril J. Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World J Hepatol 2017; 9(7): 385-390

Guo Y, Xiong Y, Sheng Q, Zhao S, Wattacheril J, Flynn CR. A micro-RNA expression signature for human NAFLD progression. J Gastroenterol. 2016 Feb 13.

Garcia A, Kasim N, Gonzalez, R, Antoun J, Eckert E, Marks P, Wattacheril J, Abumrad N, Tamboli R, Walle T, Dunn J, Flynn CR. Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease. PLoS One.2015 Nov 23;10(11):e0142676. doi: 10.1371/journal.pone.0142676

Sharifnia T, Antoun J, Suarez G, Wattacheril J, Wilson K, Peek RM, Abumrad N, and Flynn CF. Hepatic TLR4 Signaling in Obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015 Aug 15;309(4):G270-8. doi: 10.1152/ajpgi.00304.2014